Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Aligos Therapeutics Inc (ALGS)

34 + Investors. Track Smart Money conviction in ALGS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -5
Streak
1Q ▼
Buyers last Q
39%

Smart Money Signals — ALGS

Based on 34 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their ALGS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 87% of 3.0Y peak

87% of all-time peak
34 funds currently hold this stock — 87% of the 3.0-year high of 39 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 6% fewer funds vs a year ago

fund count last 6Q
2 fewer hedge funds hold ALGS compared to a year ago (-6% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🔴

Heavy selling pressure — only 39% buying

12 buying19 selling
Last quarter: 19 funds sold vs only 12 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.
⚠️

Fewer new buyers each quarter (-7 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 9 → 4 → 12 → 5. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔄

Mostly new holders — 32% entered in last year

■ 6% conviction (2yr+) ■ 62% medium ■ 32% new
Only 2 funds (6%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💎

Buying through price weakness — shares -0%, value -20%

Value
-20%
Shares
0%
Last quarter: funds added -0% more shares while total portfolio value only changed -20%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
➡️

Steady discovery — ~5 new funds/quarter

12 → 9 → 4 → 12 → 5 new funds/Q
New funds entering each quarter: 9 → 4 → 12 → 5. Consistent flow of new institutional buyers without clear acceleration or slowdown.
📊

Mixed cohorts — 6% veterans, 47% new entrants

■ 6% veterans ■ 47% 1-2yr ■ 47% new
Of 34 current holders: 2 (6%) held 2+ years, 16 held 1–2 years, 16 (47%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
📋

Smaller funds dominant — 16% AUM from top-100

16% from top-100 AUM funds
10 of 34 holders rank in the top 100 by AUM, but together hold only 16% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.8
out of 10
Low Exit Risk
Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ALGS

In 2026 Q1, 12 hedge funds were net buyers of ALGS (5 opened a new position, 7 added to an existing one), while 19 reduced or exited (9 trimmed, 10 sold completely) — a 39% buyer ratio, indicating net institutional distribution. Net fund flow last quarter: -5 funds (more exits than new entries). Total institutional holders: 34.

Hedge Fund Ownership: ALGS

How many hedge funds hold ALGS — quarterly history vs. share price
Quarterly hedge fund ownership of ALGS vs. share price

Market Analysis: ALGS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ALGS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Aligos Therapeutics Inc (ALGS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ALGS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 82d ago
ALGS
-28.9%
XLV
+705.0%

ALGS outperformed XLV by -733.9% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 37d ago
ALGS
-7.5%
XLV
+691.9%

Since the filing became public, ALGS outperformed XLV by -699.4% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

4 top-rated funds 0 high-conviction
Consensus
3.0
/ 10
breadth
×
Elite
0.1
/ 10
conviction
Hedge Fund Positioning: ALGS
34 + Investors

Track Smart Money conviction in ALGS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 34 39 -12.82%
13F Shares 3M 3M -0.37%
Total Value $21M $26M -20.36%
New Positions 5 12 -7
Increased Positions 7 9 -2
Closed Positions 10 5 +5
Reduced Positions 9 6 +3
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: ALGS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

34 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ALGS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ALGS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Sio Capital Management, LLC 0.35% 327,237 $2.4M
2 Deep Track Capital, LP 0.05% 444,110 $3.3M
3 SummitTX Capital, L.P. 0.03% 148,799 $1.1M
4 Hhlr Advisors, LTD. 0.03% 76,247 $567K
5 Alyeska Investment Group, L.P. 0.01% 412,000 $3.1M
6 AlphaQuest LLC 0.01% 13,876 $129K
7 Woodline Partners LP 0.00% 177,362 $1.3M
8 Baker BROS. Advisors LP 0.00% 83,055 $617K
9 Golden State Wealth Management, LLC 0.00% 2,674 $20K
10 Marshall Wace, LLP 0.00% 267,135 $2.0M
11 XTX Topco Ltd 0.00% 14,196 $105K
12 Renaissance Technologies LLC 0.00% 100,450 $746K
13 Quadrature Capital Ltd 0.00% 10,822 $80K
14 Verition Fund Management LLC 0.00% 18,887 $140K
15 Two Sigma Advisers, LP 0.00% 13,000 $121K
16 Two Sigma Investments, LP 0.00% 23,093 $172K
17 Rockefeller Capital Management L.P. 0.00% 10,000 $74K
18 Bank of America Corp /de/ 0.00% 229,754 $1.7M
19 LPL Financial LLC 0.00% 51,500 $383K
20 Citadel Advisors LLC 0.00% 54,311 $404K
21 Vanguard Fiduciary Trust Co 0.00% 28,437 $211K
22 D. E. Shaw & Co., Inc. 0.00% 10,978 $82K
23 UBS Group AG 0.00% 37,061 $275K
24 Vanguard Capital Management LLC 0.00% 178,262 $1.3M
25 Federation des caisses Desjardins du Quebec 0.00% 950 $7K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Aligos Therapeutics Inc (ALGS)

What does the Smart Money Trend signal show for ALGS?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their ALGS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for ALGS?

Heavy selling pressure — only 39% buying: Last quarter: 19 funds sold vs only 12 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

What is the fund quality score for ALGS holders?

Smaller funds dominant — 16% AUM from top-100: 10 of 34 holders rank in the top 100 by AUM, but together hold only 16% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held ALGS?

Mostly new holders — 32% entered in last year: Only 2 funds (6%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Aligos Therapeutics Inc (ALGS) following the 2026 Q1 hedge fund 13F filings?

As of today, ALGS has moved -7.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +691.9% for the XLV sector ETF — an outperformance of -699.4%. Since the quarter end (March 31, 2026), ALGS has gained -28.9% vs +705.0% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →